Evidence map›Paper›PMID 37046619›Full record

ReviewCancers2023

Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications.

Andrew Patterson, Abdurrahman Elbasir, Bin Tian, Noam Auslander

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andrew PattersonGenomics and Computational Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2678-8006
Abdurrahman ElbasirThe Wistar Institute, Philadelphia, PA 19104, USA.
Bin TianThe Wistar Institute, Philadelphia, PA 19104, USA.
Noam AuslanderThe Wistar Institute, Philadelphia, PA 19104, USA.
The Wistar Institute · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Regulation of Alternative Cleavage and PolyadenylationR01GM084089 · NIGMS · WISTAR INSTITUTE · PI TIAN, BIN · 2008 to 2023
$6.7M
Regulation and Functions of 3'UTRs in Cellular StressR01GM129069 · NIGMS · WISTAR INSTITUTE · PI TIAN, BIN · 2018 to 2021
$1.5M
Modeling cancer evolution for prediction with neural networks: methods and applicationsR00CA252025 · NCI · WISTAR INSTITUTE · PI AUSLANDER, NOAM · 2021 to 2023
$747k
NCI NIH HHS P30 CA010815NCI NIH HHS R00 CA252025NCI NIH HHS T32 CA009171NIGMS NIH HHS R01 GM084089NIGMS NIH HHS R01 GM129069
6 · The paper itself

Abstract

Since the rise of next-generation sequencing technologies, the catalogue of mutations in cancer has been continuously expanding. To address the complexity of the cancer-genomic landscape and extract meaningful insights, numerous computational approaches have been developed over the last two decades. In this review, we survey the current leading computational methods to derive intricate mutational patterns in the context of clinical relevance. We begin with mutation signatures, explaining first how mutation signatures were developed and then examining the utility of studies using mutation signatures to correlate environmental effects on the cancer genome. Next, we examine current clinical research that employs mutation signatures and discuss the potential use cases and challenges of mutation signatures in clinical decision-making. We then examine computational studies developing tools to investigate complex patterns of mutations beyond the context of mutational signatures. We survey methods to identify cancer-driver genes, from single-driver studies to pathway and network analyses. In addition, we review methods inferring complex combinations of mutations for clinical tasks and using mutations integrated with multi-omics data to better predict cancer phenotypes. We examine the use of these tools for either discovery or prediction, including prediction of tumor origin, treatment outcomes, prognosis, and cancer typing. We further discuss the main limitations preventing widespread clinical integration of computational tools for the diagnosis and treatment of cancer. We end by proposing solutions to address these challenges using recent advances in machine learning.

Indexed as

bioinformaticscancer driverscancer genomicsclinical predictorsmachine learningmutation signatures

Identifiers

PMID37046619
PMCPMC10093138
OpenAlexW4360847948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.